The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, complet | Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former ...
President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...
The head of the FDA’s artificial intelligence-focused Digital Center of Excellence, Troy Tazbaz, is departing the agency, ...
After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...
During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. | This week on “The Top ...
The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...
A sugar produced by soil bacteria may be able to stop the loss of skin pigment caused by vitiligo. | A sugar produced by ...
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback